Patents by Inventor Katerina Leftheris

Katerina Leftheris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thiazolyl-based compounds useful as kinase inhibitors
    Patent number: 7169771
    Abstract: The present invention provides thiazolyl-based compounds of formula (I), useful for treating p38 kinase-associated conditions, wherein ring A is phenyl or pyridyl, and X, Y, B, R2, R3, Z1 m and n are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: January 30, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: John Hynes, Hong Wu, Katerina Leftheris, Chunjian Liu, Jagabandhu Das, Robert V. Moquin
  • Pyrrolo-triazine aniline compounds useful as kinase inhibitors
    Patent number: 7160883
    Abstract: Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R6, X and Z are as described in the specification.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: January 9, 2007
    Assignee: Bristol-Myers-Squibb Company
    Inventors: Alaric Dyckman, John Hynes, Katerina Leftheris, Chunjian Liu, Stephen T. Wrobleski
  • Pyrazole-amine compounds useful as kinase inhibitors
    Patent number: 7151113
    Abstract: The present invention provides pyrazole derived compounds of formula (I) useful for treating p38 kinase-associated conditions, where W, X, R1, R2, R3, R4, R5, R6 and m are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.
    Type: Grant
    Filed: May 3, 2004
    Date of Patent: December 19, 2006
    Assignee: Bristol Myers Squibb Company
    Inventors: Alaric J. Dyckman, Jagabandhu Das, Katerina Leftheris, Chunjian Liu, Robert V. Moquin, Stephen T. Wrobleski
  • N-heterocyclic inhibitors of TNF-alpha expression
    Publication number: 20060276488
    Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula (I): Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.
    Type: Application
    Filed: July 12, 2006
    Publication date: December 7, 2006
    Inventors: Gulzar Ahmed, Axel Metzger, Ian Henderson, David Diller, Jun Wen, Stephen Wrobleski, Katerina Leftheris, Chunjian Liu
  • Pyrazole-amine compounds useful as kinase inhibitors
    Publication number: 20060247247
    Abstract: The present invention provides pyrazole derived compounds of formula (I) useful for treating p38 kinase-associated conditions, where W, X, R1, R2, R3, R4, R5, R6 and m are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.
    Type: Application
    Filed: June 28, 2006
    Publication date: November 2, 2006
    Inventors: Alaric Dyckman, Jagabandhu Das, Katerina Leftheris, Chunjian Liu, Robert Moquin, Stephen Wrobleski
  • Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
    Publication number: 20060178388
    Abstract: Compounds having the formula (I), and pharmaceutically acceptable salts, and solvates thereof, are useful as kinase inhibitors, wherein: two of X1, X2, and X3 are N, and the remaining one of X1, X2, and X3 is —CR1; R1 is hydrogen or —CN; and N, G, Z, R2, R3, R4, R5, and R6 are described in the specification. Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.
    Type: Application
    Filed: February 1, 2006
    Publication date: August 10, 2006
    Inventors: Stephen Wrobleski, Shuqun Lin, Katerina Leftheris, Liqi He, Steven Seitz, Tai-An Lin, Wayne Vaccaro
  • Process for preparing pyrrolotriazine kinase inhibitors
    Patent number: 7034151
    Abstract: An improved process for the preparation of certain pyrrolotriazine compounds is disclosed. The compounds exhibit utility as kinase inhibitors.
    Type: Grant
    Filed: February 5, 2004
    Date of Patent: April 25, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bang-Chi Chen, Rulin Zhao, Joseph Edward Sundeen, Katerina Leftheris, John Hynes, Stephen T. Wrobleski
  • Process for preparing pyrrolotriazine kinase inhibitors
    Publication number: 20060041124
    Abstract: An improved process for the preparation of certain pyrrolotriazine compounds is disclosed. The compounds exhibit utility as kinase inhibitors.
    Type: Application
    Filed: October 14, 2005
    Publication date: February 23, 2006
    Inventors: Bang-Chi Chen, Rulin Zhao, Joseph Sundeen, Katerina Leftheris, John Hynes, Stephen Wrobleski
  • Tricyclic-heteroaryl compounds useful as kinase inhibitors
    Publication number: 20060019928
    Abstract: The present invention relates to compounds having the formula, wherein, Q is optionally substituted aryl or heteroaryl, R1 is hydrogen or C1-4alkyl, and R2, R3, R4 and R5 are hydrogen or optional substituents as defined in the specification.
    Type: Application
    Filed: June 29, 2005
    Publication date: January 26, 2006
    Inventors: James Lin, Stephen Wrobleski, Chunjian Liu, Katerina Leftheris
  • Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
    Patent number: 6962915
    Abstract: Compounds having the formula (I), and pharmaceutically acceptable salts or prodrugs thereof, are useful as kinase inhibitors, wherein Y is —C(?O)NR1—, —NR1C(?O)—, —NR1C(?O)NR1—, —NR1SO2—, —SO2NR1—, —C(?O)—, —OC(?O)—, or —CO2—; B is alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxy, alkoxy, aryl, cycloalkyl, heteroaryl, and heterocyclo; or when Y is —C(?O)NR1—, B also may be selected from —C(?O)R8, —C(?O)NR8R9, and —CO2R8; R1 is hydrogen, C1-4alkyl, or substituted C1-4alkyl; R2 is hydrogen or C1-4alkyl; R3 is hydrogen, methyl, perfluoromethyl, hydroxy, methoxy, halogen, cyano, NH2, or NH(CH3); and R4, R5, R6, R7, R8, and R9 are as defined in the specification.
    Type: Grant
    Filed: May 19, 2003
    Date of Patent: November 8, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jagabandhu Das, Chunjian Liu, Robert V. Moquin, Katerina Leftheris
  • N-heterocyclic inhibitors of TNF-alpha expression
    Publication number: 20050239770
    Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.
    Type: Application
    Filed: June 2, 2005
    Publication date: October 27, 2005
    Inventors: Kevin Moriarty, Yvonne Shimshock, Gulzar Ahmed, Junjun Wu, James Wen, Wei Li, Shawn Erickson, Jeffrey Letourneau, Edward McDonald, Katerina Leftheris, Stephen Wrobleski, Zahid Hussain, Ian Henderson, Axel Metzger, John Baldwin, Alaric Dyckman
  • Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
    Publication number: 20050159424
    Abstract: The present invention relates to compounds having the formula, and pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, or pyrazinyl ring; R2 is alkyl or an amino group as defined herein; and Z is optionally-substituted oxadiazolyl or —C(?O)NR6, wherein R6 is lower alkyl or cyclopropyl. The compounds are surprisingly advantageous in preparing pharmaceutical compositions for treating p38 kinase related conditions and/or in methods of treating conditions associated with the activity of p38 kinase in a patient.
    Type: Application
    Filed: May 3, 2004
    Publication date: July 21, 2005
    Inventors: Alaric Dyckman, Jagabandhu Das, Katerina Leftheris, Chunjian Liu, Rulin Zhao, Bang-Chi Chen, Stephen Wrobleski
  • Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
    Publication number: 20050143398
    Abstract: Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R, R1, R2, R5, R6a, R6b, J, K, X and Z are as described in the specification.
    Type: Application
    Filed: October 21, 2004
    Publication date: June 30, 2005
    Inventors: Jagabandhu Das, John Hynes, Katerina Leftheris, Shuqun Lin, Stephen Wrobleski, Hong Wu
  • N-heterocyclic inhibitors of TNF-? expression
    Patent number: 6906067
    Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: June 14, 2005
    Assignees: Bristol-Myers Squibb Company, Pharmaceopeia, Inc.
    Inventors: Kevin Joseph Moriarty, Yvonne Shimshock, Gulzar Ahmed, Junjun Wu, James Wen, Wei Li, Shawn David Erickson, Jeffrey John Letourneau, Edward McDonald, Katerina Leftheris, Stephen T. Wrobleski, Zahid Hussain, Ian Henderson, Axel Metzger, John J. Baldwin, Alaric J. Dyckman
  • Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
    Publication number: 20050107462
    Abstract: Methods of preparing kinase inhibiting pharmaceutical compounds having the formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein R1 through R6 and Z are as described in the specification. The methods according to the invention utilize an amination process, in which a pyrrole is reacted with a haloamine, preferably chloramine. This step is followed by cyclization to form the pyrrolotriazine core.
    Type: Application
    Filed: December 22, 2004
    Publication date: May 19, 2005
    Inventors: Jollie Godfrey, John Hynes, Alaric Dyckman, Katerina Leftheris, Zhongping Shi, Stephen Wrobleski, Wendel William Doubleday, John Grosso
  • Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
    Patent number: 6867300
    Abstract: Methods of preparing kinase inhibiting pharmaceutical compounds having the formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein R1 through R6 and Z are as described in the specification. The methods according to the invention utilize an amination process, in which a pyrrole is reacted with a haloamine, preferably chloramine. This step is followed by cyclization to form the pyrrolotriazine core.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: March 15, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jollie Duaine Godfrey, Jr., John Hynes, Jr., Alaric J. Dyckman, Katerina Leftheris, Zhongping Shi, Stephen T. Wrobleski, Wendel William Doubleday, John A. Grosso
  • Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
    Publication number: 20050043306
    Abstract: Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R6, X and Z are as described in the specification.
    Type: Application
    Filed: October 3, 2003
    Publication date: February 24, 2005
    Inventors: Katerina Leftheris, Stephen Wrobleski, Alaric Dyckman
  • Pyrazole-amide compounds useful as kinase inhibitors
    Publication number: 20050004176
    Abstract: The present invention provides pyrazole derived compounds of formula (I) useful for treating p38 kinase-associated conditions, where G, X, R1, R2, R3, R4, R5, R6 and m are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.
    Type: Application
    Filed: May 3, 2004
    Publication date: January 6, 2005
    Inventors: Alaric Dyckman, Jagabandhu Das, Katerina Leftheris, Chunjian Liu, Robert Moquin, Stephen Wrobleski
  • Purine inhibitors of phosphodiesterase (PDE) 7
    Patent number: 6838559
    Abstract: Purine phosphodiesterase 7 (PDE 7) inhibitors of the following formulas wherein R1, Z, Y and J are described herein, and analogs thereof are provided which are useful in treated T-cell mediated diseases. R2 is defined by the following (a) heteroaryl, or heterocyclo, either of which may be optionally substituted with one to three groups T1, T2, T3; (b) aryl substituted with one to three groups T1, T2, T3 provided that at least one of T1, T2, T3 is other than H; or (c) aryl fused to a heteroaryl or heterocyclo ring wherein the combined ring system may be optionally substituted with one to three groups T1, T2, T3.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: January 4, 2005
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Wayne Vaccaro, Jacques Y. Roberge, Katerina Leftheris, William J. Pitts, Joseph Barbosa
  • Pyrazole-amine compounds useful as kinase inhibitors
    Publication number: 20040248853
    Abstract: The present invention provides pyrazole derived compounds of formula (I) 1
    Type: Application
    Filed: May 3, 2004
    Publication date: December 9, 2004
    Inventors: Alaric J. Dyckman, Jagabandhu Das, Katerina Leftheris, Chunjian Liu, Robert V. Moquin, Stephen T. Wrobleski